TY - JOUR
T1 - Array comparative genomic hybridization analysis of adult acute leukemia patients
AU - Yasar, Duygu
AU - Karadogan, Ihsan
AU - Alanoglu, Guchan
AU - Akkaya, Bahar
AU - Luleci, Guven
AU - Salim, Ozan
AU - Timuragaoglu, Aysen
AU - Toruner, Gokce A.
AU - Berker-Karauzum, Sibel
N1 - Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2010/3
Y1 - 2010/3
N2 - We have performed a retrospective array-based comparative hybridization (array-CGH) study on 41 acute leukemia samples [n = 17 acute lymphoblastic leukemia (ALL) patients only at diagnosis, n = 3 ALL patients both at diagnosis and relapse; n = 20 acute myeloid leukemia (AML) patients only at diagnosis and n = 1 AML patient both at diagnosis and relapse] using an Agilent 44 K array. In addition to previously detected cytogenetic aberrations, we observed cryptic aberrations in 95% of ALL and 90.5% of AML cases. ALL-specific recurrent abnormalities were RB1 (n = 3), PAX5 (n = 4), and CDKN2B (n = 3) deletions; AML-specific recurrent abnormalities were HOXA9 and HOXA10 (n = 2) deletions and NOTCH1 duplication (n = 2). Recurrent duplication of the ELK1 oncogene was observed in both ALL (n = 2) and AML (n = 3) cases. Our results demonstrate that oligo-array CGH (oaCGH) is an effective method for defining copy number alterations and identification of novel recurring unbalanced abnormalities. At least for now, however, the use of oaCGH for routine diagnosis still has some restrictions.
AB - We have performed a retrospective array-based comparative hybridization (array-CGH) study on 41 acute leukemia samples [n = 17 acute lymphoblastic leukemia (ALL) patients only at diagnosis, n = 3 ALL patients both at diagnosis and relapse; n = 20 acute myeloid leukemia (AML) patients only at diagnosis and n = 1 AML patient both at diagnosis and relapse] using an Agilent 44 K array. In addition to previously detected cytogenetic aberrations, we observed cryptic aberrations in 95% of ALL and 90.5% of AML cases. ALL-specific recurrent abnormalities were RB1 (n = 3), PAX5 (n = 4), and CDKN2B (n = 3) deletions; AML-specific recurrent abnormalities were HOXA9 and HOXA10 (n = 2) deletions and NOTCH1 duplication (n = 2). Recurrent duplication of the ELK1 oncogene was observed in both ALL (n = 2) and AML (n = 3) cases. Our results demonstrate that oligo-array CGH (oaCGH) is an effective method for defining copy number alterations and identification of novel recurring unbalanced abnormalities. At least for now, however, the use of oaCGH for routine diagnosis still has some restrictions.
UR - http://www.scopus.com/inward/record.url?scp=77249168761&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77249168761&partnerID=8YFLogxK
U2 - 10.1016/j.cancergencyto.2009.11.018
DO - 10.1016/j.cancergencyto.2009.11.018
M3 - Article
C2 - 20193845
AN - SCOPUS:77249168761
SN - 0165-4608
VL - 197
SP - 122
EP - 129
JO - Cancer Genetics and Cytogenetics
JF - Cancer Genetics and Cytogenetics
IS - 2
ER -